



(51) International Patent Classification:

C07D 217/26 (2006.01) A61K 31/4725 (2006.01)
C07C 255/58 (2006.01) A61P 5/26 (2006.01)
C07D 401/04 (2006.01) A61P 5/28 (2006.01)
C07D 417/04 (2006.01) A61P 21/00 (2006.01)
C07D 205/04 (2006.01) A61P 19/00 (2006.01)
C07D 207/08 (2006.01) A61P 25/00 (2006.01)
C07D 285/10 (2006.01) A61P 3/00 (2006.01)
C07D 211/22 (2006.01)

(21) International Application Number:

PCT/IB2013/060381

(22) International Filing Date:

25 November 2013 (25.11.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/732,617 3 December 2012 (03.12.2012) US

(71) Applicant: **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, New York 10017 (US).

(72) Inventors: **ANDERSON, James, Thomas**; 5 Howell Avenue, Hillsdale, New Jersey 07642 (US). **CHEKLER, Eugene, Lvovich, Piatnitski**; 2112 Main Street, Concord, Massachusetts 01742 (US). **ELLSWORTH, Edmund, L.**; 730 U Avenue E, Vicksburg, Michigan 49097 (US). **ERICKSON, Bruce, Kipp**; 1300 West E Avenue, Kalamazoo, Michigan 49009 (US). **GILBERT, Adam, Matthew**; 178 Denison Drive, Guilford, Connecticut 06437 (US). **RICKETTS, Anthony, P.**; 2397 Cross Country Drive, Kalamazoo, Michigan 49009 (US). **THOMPSON, David,**

P.; 729 Windamere Boulevard, Battle Creek, Michigan 49015 (US). **UNWALLA, Rayomand, Jal**; 22 Fox Run Road, Bedford, Massachusetts 01730 (US). **VERHOEST, Patrick, Robert**; 23 Calvin Road, Newton, Massachusetts 02460 (US).

(74) Agent: **KLEIMAN, Gabriel, L.**; Pfizer Inc., 235 East 42nd Street, New York, New York 10017 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to the identity of the inventor (Rule 4.17(i))

[Continued on next page]

(54) Title: NOVEL SELECTIVE ANDROGEN RECEPTOR MODULATORS



(57) Abstract: The present invention relates to a compound of Formula 1, 2 or 3; wherein A is N or $-\text{CR}_0-$, where R_0 is hydrogen, C_1 - C_6 linear or branched chain alkyl, etc., Z is $-\text{CR}_e-$, or, $-\text{N}-$, where R_e is hydrogen, C_1 - C_6 linear or branched chain alkyl, etc.; R_1 is hydrogen, C_1 - C_6 linear or branched chain alkyl, etc.; R_2 are independently hydrogen or C_1 - C_6 linear or branched chain alkyl; R_3 and R_4 are independently hydrogen, C_1 - C_6 linear or branched chain alkyl, etc.; R_5 and R_6 are independently hydrogen or C_1 - C_6 linear or branched chain alkyl, etc.; R_8 is hydrogen, C_1 - C_6 linear or branched chain alkyl, etc.; R_9 and R_{10} are independently hydrogen or C_1 - C_6 linear or branched chain alkyl, etc.; Q is $-\text{CO}-$, $-(\text{CH}_2)_q-$, $-(\text{CHR}_s)_q-$, or $-(\text{CR}_s \text{R}_t)_q-$, where R_s and R_t are independently C_1 - C_6 linear or branched chain alkyl, aryl, alkylaryl, heteroaryl or alkylheteroaryl; where q is 0, 1, 2, or 3; and, where n is 0, 2, 3, 4 or 5; or, a pharmaceutically acceptable salt thereof, to compositions containing such compounds; and to the uses of such compounds in the treatment of various diseases, particularly, those affected or mediated by the androgen receptor.



-
- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- Published:**
- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*